Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Share-based Compensation (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Share-based Compensation for 7 consecutive years, with $20.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 32.33% to $20.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $94.2 million, a 21.89% decrease, with the full-year FY2025 number at $94.2 million, down 21.89% from a year prior.
  • Share-based Compensation was $20.4 million for Q4 2025 at Beam Therapeutics, down from $22.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $31.6 million in Q2 2024 to a low of $4.6 million in Q1 2021.
  • A 5-year average of $22.1 million and a median of $22.7 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 330.54% in 2021, then crashed 32.33% in 2025.
  • Beam Therapeutics' Share-based Compensation stood at $15.5 million in 2021, then soared by 45.14% to $22.5 million in 2022, then grew by 0.52% to $22.6 million in 2023, then skyrocketed by 33.61% to $30.2 million in 2024, then plummeted by 32.33% to $20.4 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Share-based Compensation are $20.4 million (Q4 2025), $22.7 million (Q3 2025), and $24.4 million (Q2 2025).